Share this

Hcc

Pembrolizumab Keytruda

KEYNOTE-224:

Open-label study in patients with HCC, previously treated with sorafenib, an anti-angiogenic TKI

N=104 participants

The median duration of follow-up – 12·3 months (IQR 7·6–15·1)1

Objective Response1